2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 149

Teaching Rare Diseases Through Role Play: Results of an Experimental Workshop About Raynaud Phenomenon
Abstract Number: 2662

Temporal Artery Biopsy Lengths in Alberta: Which Surgical Subspecialty Achieves Optimal Biopsy Lengths?
Abstract Number: 566

Temporal Relationship Between Enteropathic Spondylitis Symptoms/diagnosis and Inflammatory Bowel Diseases Diagnosis: HUR-BIO Real Life Results
Abstract Number: 622

Ten-year Atherosclerotic Cardiovascular Disease Risk Scores in Axial Spondyloarthritis versus the General Population: A Cross-sectional Study
Abstract Number: 1005

Tendon T-cell Interactions as Drivers of Chronicity in Spondyloarthritis
Abstract Number: 294

Tendons Involvement at Early Onset of Gouty Arthritis, Ultrasonographic Study
Abstract Number: 1990

Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor
Abstract Number: 1856

Tenosynovial Aspiration by Ultrasound Guidance: Correlation and Diagnostic Implications of Tenosynovial Analysis and Ultrasound Doppler Signal
Abstract Number: 2019

Tenosynovitis at the Metatarsophalangeal Joints, a Novel Feature of RA: Results from an Anatomical and Large Magnetic Resonance Imaging Study of Tendon Sheaths of the Forefoot
Abstract Number: 1807

Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease
Abstract Number: 2174

Test-Retest Reliability and Validity of a Mobile Health Application to Automate the 30 Seconds Chair Stand Test – Preliminary Data to Create a Contemporary Instrument for Randomized Clinical Trials
Abstract Number: 2847

Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA
Abstract Number: 1202

Testing Rheumatoid Arthritis Performance Measures to Optimize Treat to Target Strategies
Abstract Number: 1044

TGF-β Isoforms Modulate the RNA Cargo of Extracellular Vesicles (Exosomes) Isolated from Cultured Normal Human Lung Microvascular Endothelial Cells: A Mechanistic Link Between Endothelial Cell Dysfunction and the Establishment of a Profibrotic Phenotype in SSc?
Abstract Number: 2506

The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].